Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 14 peer-reviewed journal articles Updated
Orthopedic Oncology

The Biology of TGCT: The CSF1 Gene Mechanism

At a Glance

Tenosynovial Giant Cell Tumor (TGCT) is uniquely driven by a genetic mutation in the CSF1 gene. Only 2-10% of the tumor contains diseased cells; these act as "rogue bosses" that overproduce CSF1, recruiting normal immune cells to form the tumor mass and cause destructive joint inflammation.

While the word “tumor” often brings to mind a solid mass of cancer cells, Tenosynovial Giant Cell Tumor (TGCT) is biologically unique. In a typical TGCT, the vast majority of the “tumor” is actually made up of normal inflammatory cells [1][2]. The actual “diseased” cells—the ones with the genetic glitch—often make up only about 2% to 10% of the total mass [1][3].

Understanding why this happens requires looking at a specific genetic event and a phenomenon called the paracrine effect [1].

The Genetic Glitch: The “Rogue Boss”

The process begins with a specific genetic change known as a translocation, labeled as t(1;2)(p13;q37) [1][4].

In simple terms, a piece of chromosome 1 and a piece of chromosome 2 swap places. This swap puts a gene called CSF1 (Colony Stimulating Factor 1) in the wrong neighborhood [1]. Specifically, it gets stuck next to a very “loud” promoter gene (COL6A3) that is always turned on in your joints [1]. As a result, the cell starts pumping out massive amounts of CSF1 protein [1].

The Paracrine Effect: The “Megaphone” Analogy

Think of the few cells with this genetic swap as “Rogue Bosses.” These bosses aren’t doing the actual damage themselves, but they have a powerful “Megaphone” (the overproduced CSF1 protein) [1][3].

The paracrine effect works like this:

  1. The Rogue Bosses use their CSF1 “megaphones” to broadcast a signal across the joint [1].
  2. Normal Immune Cells (called macrophages) in your body have “ears” (receptors) that are tuned specifically to the CSF1 frequency [1][5].
  3. The Recruitment: Hearing the signal, thousands of normal, healthy immune cells rush into the joint, thinking there is an emergency [1].
  4. The Crowd: These recruited cells clump together, forming the physical mass of the tumor. They also fuse together to create multinucleated giant cells [1][6].

Why the Joint Gets Destroyed

The frustrating reality of TGCT is that these normal immune cells, once recruited, start acting like a destructive mob. Because they are primed for an immune response, they release inflammatory chemicals and enzymes [7][8].

Specifically, they can turn into or recruit osteoclasts—cells designed to break down bone [8]. This is why TGCT is locally aggressive; the recruited crowd eventually begins to eat away at the joint’s cartilage and bone, leading to the osseous erosions (bone pits) seen on MRIs [7][8].

Targeted Therapy: Silencing the Megaphone

Because doctors now understand this “Boss and Megaphone” biology, they have developed treatments called CSF1R inhibitors (such as pexidartinib or vimseltinib) [9][10]. You can read more about these in the Systemic Therapies section.

These medications work by “plugging the ears” of the normal immune cells. They block the CSF1R receptor so the cells can no longer hear the “Rogue Boss” calling them [11][12]. When the signal is silenced, the recruited crowd disperses or never arrives in the first place, which can shrink the tumor and reduce joint inflammation [5][13].

By targeting the communication between cells rather than trying to kill every cell like traditional chemotherapy, these therapies represent a major shift in how we manage the more aggressive, diffuse forms of TGCT [5][14].

Common questions in this guide

What causes a Tenosynovial Giant Cell Tumor to grow?
TGCT is caused by a genetic swap that makes a few cells overproduce a protein called CSF1. This protein acts like a megaphone, recruiting thousands of normal immune cells into the joint, which clump together to form the actual tumor mass.
Is a TGCT tumor made entirely of cancer cells?
No, in a typical TGCT, the diseased cells with the genetic glitch only make up about 2% to 10% of the mass. The vast majority of the tumor consists of normal, healthy immune cells that have been mistakenly recruited to the joint.
How does TGCT cause bone and joint damage?
The immune cells recruited to the tumor are primed for an immune response and release inflammatory chemicals. They can also turn into osteoclasts, which are cells that naturally break down bone, leading to joint destruction and bone pits.
How do targeted therapies for TGCT work?
Targeted therapies, known as CSF1R inhibitors, work by blocking the receptors on normal immune cells so they can no longer hear the signal from the diseased cells. When this communication is blocked, the immune cells stop gathering, which can shrink the tumor and reduce inflammation.
Does my pathology report need to show the CSF1 gene mutation?
Identifying the CSF1 translocation or overexpression in your pathology report confirms the biological driver of your TGCT. This information helps your doctor determine if you are a candidate for targeted treatments like CSF1R inhibitors.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Does my pathology report confirm the presence of the CSF1 translocation or overexpression?
  2. 2.If my tumor is mostly made of recruited normal cells, does that mean shrinking it is easier than if it were a typical cancer?
  3. 3.Am I a candidate for targeted therapy that blocks the CSF1R receptor?
  4. 4.How is the tumor causing bone destruction—is it the giant cells that are responsible?
  5. 5.What are the side effects of medications that target the CSF1R pathway, and how do we monitor them?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (14)
  1. 1

    Tenosynovial giant cell tumor.

    Kager M, Kager R, Fałek P, et al.

    Folia medica Cracoviensia 2022; (62(2)):93-107 doi:10.24425/fmc.2022.141702.

    PMID: 36256897
  2. 2

    Identification of a potential relationship between pigmented villonodular synovitis and atherosclerosis using comprehensive bioinformatics analyses.

    Chen S, Jia H, Zheng G, et al.

    Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 2026; 1-10 doi:10.1080/1354750X.2026.2625237.

    PMID: 41630435
  3. 3

    Tenosynovial giant cell tumor (TGCT): Mechanisms and advances in targeted treatments.

    Xu H, Li Y, Lin N, et al.

    Critical reviews in oncology/hematology 2025; (216()):104951 doi:10.1016/j.critrevonc.2025.104951.

    PMID: 40953758
  4. 4

    Pigmented Villonodular Synovitis: A Comprehensive Review and Proposed Treatment Algorithm.

    Stephan SR, Shallop B, Lackman R, et al.

    JBJS reviews 2016; (4(7)) doi:10.2106/JBJS.RVW.15.00086.

    PMID: 27509331
  5. 5

    Medical Management of Tenosynovial Giant Cell Tumor.

    Palmerini E, Trent JC, Hornicek FJ

    Current oncology reports 2025; (27(7)):844-855 doi:10.1007/s11912-025-01679-x.

    PMID: 40392406
  6. 6

    MRI and 18F-FDG PET/CT findings of a giant cell tumor of the tendon sheath of the knee joint (pigmented villonodular synovitis): A case report and literature review.

    Liu X, Xu H, Jiang T, et al.

    Hellenic journal of nuclear medicine 2021; (24(2)):149-154 doi:10.1967/s002449912355.

    PMID: 34352050
  7. 7

    Managing Extensive Pigmented Villonodular Synovitis with Wide Resection and Endoprosthesis Replacement at the Elbow and Ankle Joints: A Mid-term Outcome.

    Ajit Singh V, Haseeb A, Yasin NF

    Indian journal of orthopaedics 2026; (60(1)):235-243 doi:10.1007/s43465-025-01472-9.

    PMID: 41541034
  8. 8

    Identification of potential diagnostic biomarkers for tenosynovial giant cell tumour by integrating microarray and single-cell RNA sequencing data.

    Chen C, Zheng L, Zeng G, et al.

    Journal of orthopaedic surgery and research 2023; (18(1)):905 doi:10.1186/s13018-023-04279-2.

    PMID: 38017559
  9. 9

    A Phase 3 Study of the Efficacy and Safety of Pexidartinib in East Asian Patients with Tenosynovial Giant Cell Tumor.

    Xu H, Wu PK, Ye Z, et al.

    Oncology and therapy 2025; (13(4)):1025-1039 doi:10.1007/s40487-025-00365-z.

    PMID: 40841499
  10. 10

    Vimseltinib versus a placebo in patients with tenosynovial giant cell tumor: a plain language summary of the MOTION phase 3 trial.

    Bernthal NM, Stern S, Blay JY

    Future oncology (London, England) 2024; (20(39)):3183-3192 doi:10.1080/14796694.2024.2398893.

    PMID: 39378061
  11. 11

    Long-term outcomes of pexidartinib in tenosynovial giant cell tumors.

    Gelderblom H, Wagner AJ, Tap WD, et al.

    Cancer 2021; (127(6)):884-893 doi:10.1002/cncr.33312.

    PMID: 33197285
  12. 12

    Update on Tenosynovial Giant Cell Tumor, an Inflammatory Arthritis With Neoplastic Features.

    Robert M, Farese H, Miossec P

    Frontiers in immunology 2022; (13()):820046 doi:10.3389/fimmu.2022.820046.

    PMID: 35265077
  13. 13

    Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.

    Gelderblom H, Cropet C, Chevreau C, et al.

    The Lancet. Oncology 2018; (19(5)):639-648 doi:10.1016/S1470-2045(18)30143-8.

    PMID: 29571946
  14. 14

    Prospects of Treating Tenosynovial Giant Cell Tumor through Pexidartinib: A Review.

    Alsayadi YMMA, Chawla PA

    Anti-cancer agents in medicinal chemistry 2021; (21(12)):1510-1519 doi:10.2174/1871520620999201102123555.

    PMID: 33143617

This page provides educational information about the biological mechanisms of TGCT. It does not replace professional medical advice, and you should always consult your healthcare team regarding your specific genetic profile and treatment options.

Get notified when new evidence is published on Tenosynovial giant cell tumor.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.